Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution

Authors:

Abstract
Key Points: Moderate-dose cyclophosphamide is associated with an unacceptable rate of toxicity in SAA, as in high-dose cyclophosphamide. Moderate-dose cyclophosphamide is an active regimen but is associated with a low response and does not prevent relapse or clonal evolution.

This publication has 24 references indexed in Scilit: